Mitt Romney, a former Republic presidential nominee, recently made his health record public when he announced that he had undergone a prostate cancer prognosis. It was not clear why he took that decision, but political analysts opine that he might be preparing himself to run for the U.S Senate seat which will soon be left vacant by the current occupant, Orrin Hatch. According to Dr. David Samadi, the successful surgery was conducted by Dr. Thomas Ahlering at UC Hospital, California. The doctors at the hospital said that his prognosis was good and that there was nothing to worry about. Romney joins over 1,600 other men who were also diagnosed with prostate cancer last year. There has been an increase in the number of prostate cancer cases, and the American Cancer Society has sounded an alarm that more such cases will increase in the coming years.
Prostate cancer mainly occurs in older men of an average age of 66 years. Mitt Romney turned 70 years in March 2017. It is also important to note that Mitt Romney is not the first prominent person to undergo a successful prostate cancer surgery. In 2003, Collin Powel who was serving as secretary of state at that time underwent a similar operation at Walter Reed Army Medical Center. Another case was that of John Kerry. He was informed by doctors that he had prostate cancer at a time when he was running for president of the United States in 2002. He was also treated and declared cancer free.
According to Dr. David Samadi, when someone is diagnosed with prostate cancer, they always have two options for treatment. The first one is radiation while the other is surgery. As a result of the technology and recent discoveries such as robotic surgery, most people are opting for surgery, and that is the case with both politicians who were diagnosed with the disease. For anyone diagnosed with prostate cancer, the best thing is always to find experienced urologist for advice on how to go about with their treatment.
About Dr. David Samadi
Dr. David Samadi is a renowned urologist who has conducted several successful surgeries in his career. He is the current chairman of Urology and chief of robotic surgery at Lenox Hill Hospital, New York. He has held this position since 2012. Dr. Samdi is also an innovator. He recently came up with Samadi Modern Advanced Robotic Technique (SMART), a treatment method that has been proved to work better than the conventional methods.
Dr. Clay Siegall is the co-founder, CEO, Chairman of the Board of Directors, and president of Seattle Genetics. The company was founded in 1998 to come up with a solution on antibody-based cancer treatments. In 2011, their drug ADCETRIS was approved by the FDA for use. Dr. Siegall has been instrumental in the raising of capital for various activities. In 2001, he managed to raise $675 million through an initial public offering, private and public financing. Dr. Siegell holds a Ph.D. holder in the field of Genetics from George Washington University. He also holds a B.S. from the University of Maryland in the field of Zoology.
Dr. Siegell has worked with various pharmaceutical companies. He serves on the Board of Directors at the Alder BioPharmaceuticals. He worked with Bristol-Myers Squibb Pharmaceutical Research Institute between 1991 and 1997. He has also served with the National Cancer Institute, National Institutes of Health between 1988 and 1991. Dr. Siegall is has authored over 70 publications.
At the Seattle Genetics headquarters at the Bothell Cascade Business Park, a model of the human antibody is presented in Lego bricks. This portrays their commitment to their studying on human antibodies. Seattle Genetics believes that the same way the Lego Bricks connect with each other to create an antibody model, it’s the same way they study, manipulate and finally package the ultimate drugs to boost the antibodies that fight the cancer cell from the inside.
Seattle Genetics is valued at about $10 billion. The company consists of 900 employees. It is considered as the largest biotech company in Washington. The company heavily invests in research and marketing of their products. Its aim is to become a big pharmaceutical company. This year alone, the company expects to grow their workforce by over 200 employees.
Adcetris is currently the company’s main drug when it comes to treating Hodgkin lymphoma, a type of cancer that is associated with the lymph system and is known to spread to other parts of the body. Once the testing period is over and the drug has been proven to be successful, sales should commence. Seattle Genetics has a number of drugs that are currently in production. This is a clear indication of Clay Siegall’s desire for steering the company to greatness instead of selling to a larger company, the way other biotech companies are doing. Clay Siegall is aimed at growing Seattle Genetics to an international company. This is evident by the company’s focus on developing drugs that are internationally marketed.